Akero Therapeutics, Inc. — Cyborg Score 8/10

Strategic Profile

Its lead asset, EFX, an FGF21 analog, represents a scientifically distinct approach compared to some competitors, focusing on addressing the underlying metabolic drivers of the disease alongside liver health. Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - its treatment for fatty liver disease.

Cyborg Score Rationale

Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies, building on the results of two Phase 2b clinical trials. The company benefits from Novo Nordisk's backing, a $54 per share acquisition price with additional consideration, and operates in a high-unmet-need market with significant growth potential.

Top Insights

• Akero has been acquired by Novo Nordisk.
• The MASH market could reach $16 billion by 2033.
• Akero maintained a strong cash position, reporting cash, cash equivalents, and marketable securities of $826.3 million as of September 30, 2024.
• Novo Nordisk planned to submit Phase 3 data to regulators in the first half of 2025.

Named Competitors

• Rezdiffra — First-to-market MASH treatment
• Pegozafermin — FGF21 analog in Phase 3 for MASH
• GLP-1 therapies — Weight-loss and metabolic disease treatments

Recent Developments

• (December 2025) Novo Nordisk acquisition closed
• (October 2025) Definitive acquisition agreement announced with Novo Nordisk
• (January 2025) Announced $300 million public stock offering

Open the full interactive Akero Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.